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ABSTRACT
Objective To establish an easy and practical assay for
identifying systemic interferon (IFN) type I bioactivity in
patients with primary Sjögren’s syndrome (pSS). The IFN
type I signature is present in over half of the pSS
patients and identifies a subgroup with a higher disease
activity. This signature is currently assessed via laborious
expression profiles of multiple IFN type I-inducible genes.
Methods In a cohort of 35 pSS patients, myxovirus-
resistance protein A (MxA) was assessed as a potential
biomarker for type I IFN activity, using an enzyme
immunoassay (EIA) on whole-blood and flow cytometric
analyses (fluorescence-activated cell sorting, FACS) of
isolated CD14 monocytes. In addition, potential
biomarkers such as CD64, CD169 and B cell-activating
factor (BAFF) were simultaneously analysed in CD14
monocytes using FACS. The IFNscore, a measure for
total type I IFN bioactivity, was calculated using
expression values of the IFN type I signature genes—
IFI44, IFI44L, IFIT3, LY6E and MX1—in CD14
monocytes, determined by real-time quantitative PCR.
Results IFNscores correlated the strongest with
monocyte MxA protein (r=0.741, p<0.001) and whole-
blood MxA levels (r=0.764, p<0.001), weaker with
CD169 (r=0.495, p<0.001) and CD64 (r=0.436,
p=0.007), and not at all with BAFF protein. In
particular, whole blood MxA levels correlated with
EULAR Sjögren’s Syndrome Disease Activity Index scores
and numerous clinical pSS parameters. Interestingly,
patients on hydroxychloroquine showed reduced MxA
levels (EIA, p=0.04; FACS p=0.001).
Conclusions The MxA assays were excellent tools to
assess IFN type I activity in pSS, MxA-EIA being the
most practical. MxA levels associate with features of
active disease and are reduced in hydroxychloroquine-
treated patients, suggesting the clinical applicability of
MxA in stratifying patients according to IFN positivity.
INTRODUCTION
Primary Sjögren’s syndrome (pSS), the second most
common systemic autoimmune disease, is charac-
terised by lymphocytic infiltrates in the salivary and
lachrymal glands. Clinical manifestations range
among others from ocular and oral dryness to vas-
culitis and severe fatigue. To date, effective therapy
is not available and treatment has been mainly
symptomatic. The aetiology of pSS is largely
unknown, but evidence for a role of interferon
(IFN) type I in the pathogenesis of pSS has been
emerging.1–12 Further unravelling the complex
pathophysiology of pSS is essential for finding
disease-related biomarkers and identifying new
treatment targets.
Previously, we described the systemic upregula-
tion of IFN type I-inducible genes (IFIGs) in CD14
monocytes of pSS patients, the so-called IFN type I
signature.7 The signature is not restricted to mono-
cytes, as a similar IFN type I signature has been
observed in pSS peripheral blood mononuclear
cells (PBMCs).12 13 Assessment of the IFN type I
signature is, however, a laborious real-time PCR
technique for the expression of multiple IFIGs and
at present, another reliable immunoassay for detec-
tion of type I IFNs in blood or serum is not avail-
able. The latter is mainly due to the presence of
multiple subtypes of IFN type I.5 14 15 An easy and
functional assay to determine the presence of IFN
type I activity in the circulation would facilitate the
identification of pSS patients with IFN type I signa-
ture and further contribute to unravelling the role
of IFN type I in pSS patients.
The IFN type I signature, as defined by us,
resulted from a factor analysis of multiple tested
IFIGs and showed five genes—IFI44L, IFI44,
IFIT3, LY6E and MX1—to predict 95% of the
total variance of a large set of IFIGs. These five
genes were used to calculate an IFN type I expres-
sion score (IFNscore) per subject. Recently, we
showed this IFN type I signature in pSS monocytes
to be associated with higher EULAR Sjögren’s
Syndrome Disease Activity Index (ESSDAI) scores
as well as higher autoantibody production, rheuma-
toid factor and serum IgG, lower C3 complement
levels and higher B cell-activating factor (BAFF)
gene expression.13
The IFN type I signature is also displayed by sub-
groups of patients with systemic sclerosis (SSc), sys-
temic lupus erythematosus (SLE), dermatomyositis
and rheumatoid arthritis. Several biomarkers for
IFN type I activity have been proposed, among
others are MxA, CD64 and CD169.15–24 However,
these protein markers have never been tested sys-
tematically and simultaneously in a single (pSS)
patient group.
MxA (Myxovirus-resistance protein 1) is a key
mediator of the IFN-induced antiviral response and
is tightly regulated by type I IFNs.25–27 In SSc,
MxA gene expression was proposed as a biomarker
for type I IFN bioactivity and found to correlate
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with disease activity.15 Several methods for detection of MxA
have been previously described.15 19 28 29 Vallittu et al19 evalu-
ated their enzyme immunoassay (EIA) for MxA in whole blood
for monitoring IFN type I bioactivity in multiple sclerosis (MS)
patients treated with IFN-β. The MxA-EIA was considered by
the authors to be a faster and more reliable method compared
with flow cytometric analysis of MxA in PBMCs. To our knowl-
edge, MxA-EIA has never been used for the detection of IFN
type I activity in systemic autoimmune diseases.
In this study, we tested MxA as a candidate biomarker for sys-
temic IFN type I activity in pSS using EIA and flow cytometry
in whole blood lysates and CD14 monocytes, respectively. In
addition, the expression of CD64 (Fcγ RI), CD169 (Siglec-1)
and BAFF proteins were simultaneously assessed in CD14
monocytes, as these markers have also been proposed as biomar-
kers for IFN type I bioactivity in systemic autoimmunity.21–23 30
PATIENTS AND METHODS
Patients
According to the 2002 American-European criteria, 35 patients
positively diagnosed with pSS were recruited.2 Patients treated
with high-dose prednisone (>10 mg daily), immunosuppressants
or biologicals were excluded. Level of disease activity was
assessed using ESSDAI.31 Twenty-seven healthy controls (HCs),
neither suffering from autoimmune diseases nor using corticos-
teroids, were included. Study subjects were screened to be free
of symptoms of underlying viral infections at inclusion (table 1).
The medical ethical review board of the Erasmus MC
Rotterdam approved the study and written informed consent
was obtained.
Blood collection, preparation and monocyte isolation
Blood samples were collected in clotting tubes for serum prepar-
ation (stored at −80°C) and in sodium heparin tubes (Greiner
Bio-One, Germany). From heparinised blood, PBMCs and con-
secutively CD14 peripheral blood monocytes were isolated as
previously described.32
Measurement of complements, immunoglobulin levels
and autoantibodies
C3 and C4 complements, immunoglobulin levels (such as IgG,
IgM and IgA) and anti- Sjögren’s syndrome (SS) A/B autoanti-
body levels were measured as described previously.13
Real-time quantitative PCR
Total RNA was isolated from purified CD14 monocytes using
RNeasy columns (Qiagen, Hilden, Germany), subsequently
reverse-transcribed to cDNA using a high-capacity cDNA
Reverse Transcription Kit and real-time PCR analysis using pre-
designed primer/probe sets (Applied Biosystems, Foster City,
California, USA).32 For calculation of relative expression, all
samples were normalised to expression of the household gene
Abl. 33Fold change values were determined from normalised CT
values (CT gene – CT housekeeping gene) using the
Comparative CT (2–ΔΔCT) method (User Bulletin #2, Applied
Biosystems, Foster City, California).
Flow cytometry
Fluorescence-activated cell sorting (FACS) analysis was used to
determine surface expression and intracellular cytokine content
in purified CD14 monocytes. Membrane staining was per-
formed with fluorescently labelled antibodies: anti-CD14 (APC/
Cy7; BD Biosciences, California, USA), and either anti-CD64
(PE; Serotech, Toronto, Canada) or CD169 (Alexa Fluor-647;
Serotech) were incubated in the dark for 20 min. Subsequently,
cells were fixed (1% paraformaldehyde), permeabilised (0.5%
saponin) and stained with either anti-BAFF (FITC; R&D
Systems, Philadelphia, Pennsylvania, USA) or unconjugated
anti-MxA (ProteinTech Group, Chicago, Illinois, USA), incu-
bated in the dark for 30 min on ice; secondary antibody was
goat-anti rabbit-FITC (Supertech). Unstained cells and appropri-
ate isotype-matched controls (BD Biosciences) were used to
confirm antibody specificity. Fluorescence was assayed using
four-colour flow cytometry (FACS CaliburBeckton Dickinson &
co, San Jose, California, USA) and analysed using FlowJo
Software (TreeStar Inc, USA).
MxA EIA
MxA-EIA was executed as previously described.19 Heparinised
blood (25 μl) was lysed 1:20 and stored at −70°C until
assayed.19 Briefly (see online supplementary figure S1 for full
description), lysed whole blood samples and biotinylated
detector-monoclonal antibody (MAb) were loaded onto
MAb-coated micortitre strips and incubated overnight at 8°C;
colour reaction was stopped, absorbance450 was measured and
[MxA] read from a master standard curve. Detection limit was
10 μg/l and determined as three times the SD of eight negative
control replicates.26
IFNscore
Monocyte IFN type I signature was defined by the relative
expression of five IFIGs: IFI44L, IFI44, IFIT3, LY6E and
MxA.13 MeanHC and SDHC of each gene in the HC group were
used to standardise the expression levels. IFNscores per subject
represent the sum of these standardised scores, calculated as pre-
viously described.34 35 IFNscore distribution for the 35 patients
was bimodal, with an overlap at a score of 10. Furthermore,
HC only occasionally showed an IFNscore≥10; consequently,
values of 10 or more represent IFN type I signature positivity.13
Table 1 Patient and control characteristics
Controls
(n=27)
pSS
IFNpos
(n=21)
IFNneg
(n=14)
Demographics
Female (%) 24/27 (89) 16/21 (76) 12/14 (86)
Mean age (years)* 53±11 57 (30–85) 55 (37–76)
Disease duration (years)* NA 13.8±6.4 10.9±7.7
pSS manifestations (%)
Ocular symptoms NA 20/21 (95) 14/14 (100)
Oral symptoms NA 21/21 (100) 13/14 (93)
Positive ocular tests NA 15/21 (71) 12/14 (86)
Positive histopathology NA 11/21 (52) 7/14 (50)
Positive salivary gland tests NA 1/21 (5) 1/14 (7)
Anti-SSA NA 20/21 (95) 10/14 (71)
Anti-SSB NA 17/21 (81) 6/14 (43)
Medication status (%)
Pilocarpine NA 5/21 (24) 4/14 (29)
Hydroxychloroquine NA 13/21 (62) 13/14 (93)
Corticosteroids NA 1/21 (5) 1/14 (7)
*Data are presented as means with corresponding range or SD.
IFNpos, IFN type I signature positive; IFNneg, IFN type I signature negative; NA, not
applicable; pSS, primary Sjögren’s syndrome.
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Statistical analysis
Comparisons were analysed using the non-parametric Mann–
Whitney U test to compare medians, and an independent t test
was used to compare the means (for normally distributed
data). For correlation studies, the Spearman’s rho (rs) or
Pearson’s correlation coefficient (rp) were calculated. Values of
p<0.05 were considered statistically significant. For multiple
variable testing, values of p<0.01 (p<0.05/5) were considered
statistically significant after applying a Bonferroni correction
(n=5). Multiple group comparisons were analysed using the
Kruskal–Wallis test; statistical analysis was performed using
SPSS V.17.0.
RESULTS
Stratification of pSS patients into IFN type I signature
positive and negative patients
We used our previously described definition for the IFN type I
signature13 and reconfirmed the presence of the signature in the
current cohort—using the five indicator genes IFI44L, IFI44,
IFIT3, LY6E and MX1 (figure 1A). We stratified the patient
group as previously described in patients positive for the IFN
type I signature (IFNpos; IFNscore≥10) and patients negative
for the signature (IFNneg; IFNscore<10). Using this paradigm,
none of the HC scored above 10, whereas 21 out of 35 pSS
patients were IFNpos—a prevalence of 60% (figure 1B). In
figure 1C, gene expression for the five signature genes is
depicted in a heat map.
MxA correlates strongly to IFN type I bioactivity in pSS
To assess MxA protein as a potential biomarker for the IFN
type I signature, intracellular MxA was measured in CD14
monocytes using flow cytometry and in whole-blood lysates
using MxA-EIA.
Significant positive correlation was observed between the
IFNscores and intracellular MxA levels, as assessed by flow cyto-
metry (figure 2B). Relative mean fluorescence intensity scores of
MxA were next compared between HC, IFNneg and IFNpos
pSS patients. Quantification of CD14 monocyte MxA levels
showed a significant increase in IFNpos patients compared with
IFNneg patients and HC, whereas IFNneg patients showed
MxA levels indistinguishable from HC (figure 2C,D).
Using the MxA-EIA, MxA protein levels (μg/l) were assessed
in lysed whole blood of the same study subjects. Correlating
whole blood MxA levels to IFNscores showed a significant posi-
tive correlation (figure 2E). IFNpos patients showed significantly
elevated MxA protein levels, compared with IFNneg patients
and HC. An increase was not observed in IFNneg patients,
again showing MxA levels equal to HC (figure 2F).
CD64 and CD169 correlate weakly to IFN type I bioactivity
in pSS
We also assessed surface protein levels of CD64 and CD169
(other proposed biomarkers of IFN activity) on CD14 mono-
cytes using flow cytometry (see online supplementary figure S2).
A significant positive correlation was observed between the
IFNscore and surface expression of CD64 (figure 3A) and
CD169 (figure 3B), respectively, though with considerably lower
correlation coefficients as found for MxA (figure 2).
Figure 3D shows CD64 upregulation on monocytes of pSS
patients irrespective of their IFN positivity. For CD169 surface
expression, this was not the case as the marker was solely upre-
gulated in IFNpos pSS patients (figure 3E).
BAFF protein does not correlate to IFN type I bioactivity
in pSS
Previously, we established a positive correlation for the presence
of the IFN type I signature and BAFF mRNA gene expression in
Figure 1 (A) Relative mRNA gene
expression is shown for the five IFN
type I inducible genes of the IFN type I
signature in CD14 monocytes of
primary Sjögren’s syndrome (pSS)
patients (n=35) and healthy controls
(HCs) (n=27). Patient group is stratified
in patients negative for the IFN type I
signature (signature negative, IFNneg)
(n=14) and patients positive for
signature (IFN type I signature positive,
IFNpos) (n=21). (B) The IFNscore is
shown for HC and pSS patients. A
cut-off value of 10 is used as threshold
for IFNneg (IFNscore<10) and IFNpos
(IFNscore≥10) pSS patients. Each
symbol represents an individual
sample; horizontal lines represent the
median. p Values are shown, and to
compare medians the Mann–Whitney
U test was used. (C) Heat map
depicting gene expression of IFN type
I-inducible genes. Individual study
subjects sorted according to increasing
IFNscore (scale from blue to red) and
stratified in HC (left), IFNneg (right
upper panel) and IFNpos pSS patients
(lower panel).
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CD14 monocytes.13 This observation was confirmed in our
current cohort (see online supplementary figure S3). We there-
fore assessed intracellular BAFF protein in CD14 monocytes as
a candidate biomarker for IFN type I, using flow cytometry.
Intracellular BAFF levels showed no correlation with the
IFNscore (figure 3C; see online supplementary figure S2).
Moreover, BAFF protein levels were not significantly elevated in
pSS patients compared with HC, neither in IFNpos nor IFNneg
patients (figure 3F).
MxA correlates with disease manifestations of pSS
Previously observed association of the IFN type I signature with
high ESSDAI disease activity scores13 (reconfirmed in this study;
figure 4A) gave rise to the question whether this also holds true
for the here described potential biomarkers MxA, CD64 and
CD169. We were able to assess ESSDAI disease activity scores in
23 pSS patients of this cohort. Significant correlation was
observed between ESSDAI scores and MxA levels measured by
either assays, even though the correlation was the strongest
when the EIA was used (table 2 and figure 4B,C). For the other
biomarkers, no correlation was found (see online supplementary
table S1).
We subsequently determined whether the potential biomar-
kers were associated with classical aberrant immune parameters
of pSS such as anti-SSA and anti-SSB autoantibodies, rheuma-
toid factor, immunoglobulin levels and neutrophil counts
(table 2). In particular, whole blood MxA levels showed the
strongest and the most significant correlations with many of
these parameters; patients with autoantibodies showed higher
levels of whole blood MxA compared with patients free of
autoantibodies (figure 4D). Significant positive correlations
were also found between whole-blood MxA and rheumatoid
factor, and immunoglobulin levels (IgG, IgA and IgM) (table 2,
figure 4E). Significant negative correlations were found
between whole-blood MxA, haemoglobin levels and neutrophil
counts. Monocyte MxA(-Facs) and CD169 levels performed
less well in these comparisons (table 2; see online
supplementary table S1).
Patients on hydroxychloroquine (HCQ, Plaquenil) treatment
had significantly reduced biomarkers of IFN activity (figure 4F,
G); table 2 and figure 4G show patients on HCQ treatment to
have reduced levels of MxA, measured by EIA and FACS. HCQ
was, however, found to have no significant effect on ESSDAI
levels (figure 4H).
Figure 2 Flow cytometric analysis of MxA protein expression in CD14 monocytes from healthy controls (HCs) (n=27) and primary Sjögren’s
syndrome (pSS) patients stratified in interferon (IFN) type I signature negative (IFNneg) (n=14) and IFN type I signature positive (IFNpos) (n=21)
patients. (A) Representative dot plots show CD14 and MxA protein expression on monocytes from study subjects. (B) Correlation plot shown
between IFNscores for all study subjects and relative mean fluorescent intensity (MFI) of MxA. (C) Relative MFI of MxA is shown for healthy controls
(HCs), IFNneg and IFNpos pSS patients. (D) MxA levels are shown for IFNneg (left) and IFNpos (right) pSS patients. Representative histograms are
depicted; shaded histogram represents the isotype control, dotted line represents the HC and the solid line represents the pSS patients. Relative
expression was calculated as MxA-specific staining (MFI)/isotype control (MFI). MxA levels (mg/l) determined by MxA-enzyme immunoassay (EIA) in
whole-blood lysates of HC and pSS patients. (E) Correlation plot between IFNscores for all study subjects and intracellular MxA-EIA (mg/l) levels. (F)
MxA-EIA (mg/l) levels shown for HC and pSS patients, stratified in IFNneg and IFNpos patients. Each symbol represents an individual sample
(duplicates of two separate EIA measurements per study subject); horizontal lines represent the median. The correlation coefficients (r) and p values
are shown. For correlations, Spearman’s rho correlation test was used and to compare medians, the Mann–Whitney U test was used.
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Figure 3 Flow cytometric analysis of CD14 monocytes from healthy controls (HCs) and primary Sjögren’s syndrome (pSS) patients. Correlation
plots shown between interferon (IFN) scores for all study subjects and (A) CD64, (B) CD169 and (C) B cell-activating factor (BAFF) protein levels,
respectively. Relative mean fluorescent intensity (MFI) for (D) CD64 (E) CD169 and (F) BAFF protein levels are shown for CD14 monocytes from HC
(n=27) and pSS patients, stratified in IFN type I signature negative (IFNneg) (n=14) and IFN type Isignature positive (IFNpos) (n=21) patients. Each
symbol represents an individual sample; horizontal lines represent the median. Relative expression was calculated as protein-specific staining (MFI)/
isotype control (MFI). The correlation coefficients (r) and p values are shown. For correlations on CD64 and CD169, Spearman’s rho correlation test
was used and to compare medians, the Mann–Whitney U test was used. For BAFF, Pearson’s correlation test was used and to compare means, the
independent t test was used.
Figure 4 EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) scores stratified in (A) interferon (IFN) type I signature negative (IFNneg) and
IFN type I signature positive (IFNpos) primary Sjögren’s syndrome (pSS) patients (B) MxA (μg/l) levels as measured by the MxA-EIA; MxA<100 μg/l
(low) and MxA>100 μg /l (high). Cutoff values were determined as meanHC + 2×SDHC (C) Correlation plot is shown between EULAR Sjögren’s
Syndrome Disease Activity Index (ESSDAI) scores and MxA (μg/l) levels. (D) MxA (μg/l) levels in pSS patients in presence (+) or absence (−) of
autoantibodies; anti-SSA (divided in Ro52 and Ro60) and anti-SSB (E) immunoglobulin levels (g/l) such as IgG, IgA and IgM in pSS patients
stratified in MxA<100 μg /l and MxA>100 μg/l. Comparisons for pSS patients in presence (+) or absence (−) of hydroxychloroquine (Plaquenil)
treatment plotted for (F) the IFNscore; line represents IFNscore cutoff ≥10, (G) MxA (μg/l), as measured by the MxA-EIA and (H) ESSDAI scores.
Each symbol represents an individual sample; horizontal lines represent the median. The correlation coefficient (r) and p values (*p>0.05; **p>0.01;
***p>0.001) are shown, Spearman’s rho correlation test was used and to compare medians, the Mann–Whitney U test was used.
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DISCUSSION
Our study is the first to simultaneously assess protein levels of
MxA, CD64, CD169 and BAFF as biomarkers for IFN type I
detection. Herein, MxA was distinguished as the best functional
biomarker for systemic IFN type I activity in pSS.
MxA protein is considered as an important mediator of early
innate immune defence and its expression has been used as a
marker for IFN bioactivity in experimental as well as clinical
settings.19 27 The MxA gene, in contrast to other IFIGs, is not
directly induced by viruses and strictly depends on IFN signal-
ling.27 Furthermore, the stability of MxA protein in cells was
observed to be higher than the corresponding mRNA levels.26
We assessed intracellular MxA protein using an EIA method on
whole blood and flow cytometric analyses on circulating CD14
monocytes. In our patients, flow cytometric detection of MxA
in monocytes showed a slightly better distinction between
IFNpos and IFNneg patients within this pSS group, relative to
the EIA in whole blood. Nevertheless, the MxA-EIA was a more
practical assay as it requires only 25 ml of whole blood—
obtained during routine blood collection and easily stored at
−70°C to the time of assessment—without necessity of labori-
ous PBMC isolation and subsequent monocyte isolation. Vallittu
et al,19 who previously validated the MxA-EIA for monitoring
MS patients treated with IFN-β, concluded the EIA favourable
for large-scale clinical application due to its high level of stand-
ardisation and reproducibility. We also experienced the EIA to
be less variable than FACS (data not shown). This report shows
whole-blood MxA levels measured by EIA to have the strongest
correlation with features of active pSS, that is, with higher
ESSDAI scores, anti-SSA/SSB antibodies, rheumatoid factor,
immunoglobulin levels, lower haemoglobulin levels and neutro-
phil counts. We found no association with complement con-
sumption as previously found for the IFNscore.13 On the basis
of these observations, we propose to use the MxA-EIA for iden-
tification of IFN type I bioactivity in pSS.
Alongside MxA, we also considered CD64, CD169 and BAFF
as candidates, observing a significant correlation between CD64
and CD169 and the IFNscore, be it with a relatively low correl-
ation coefficient.
CD64, the high-affinity Fc-gamma receptor I (Fcγ RI) recog-
nising Fc portion of IgG, is exclusively expressed on myeloid
cells and found to correlate with IFIG expression in SLE.21 23
Levels of CD64 on monocytes did neither correlate with IFN
type I activity, nor with the clinical and laboratory parameters.
In contrast, the surface marker was overexpressed in all pSS
patients. We therefore consider it as a marker of systemic auto-
immunity in general.36
CD169, also termed sialoadhesin (Siglec-1), previously identi-
fied as a biomarker for IFN type I activation in SLE, was found
to correlate with disease severity.16 Also in SSc, elevated CD169
levels were found on monocytes.17 In our hands, CD169 was
elevated in IFNpos pSS patients and correlated to several clinical
and laboratory parameters, even though not as strongly as the
MxA assays.
BAFF overexpression has been observed in serum, salivary
glands and monocytes in pSS patients.18 20 37 38 We previously
Table 2 Comparisons of the MxA biomarker—assessed by MxA-EIA and MxA-FACS—with clinical and laboratory parameters of pSS patients
Variable MxA-EIA MxA-Facs
N r p Value N r p Value
ESSDAI score 24 0.65 <0.01 28 0.45 0.02
Laboratory parameters
Rf (IE/ml) 22 0.57 0.01 26 0.33 n.s.
C3 (g/l)* 27 0.03 n.s. 33 −0.17 n.s.
C4 (g/l) 27 −0.07 n.s. 33 −0.43 n.s.
IgG (g/l)* 29 0.52 <0.01 35 0.40 0.02
IgA (g/l) 27 0.44 0.02 33 0.41 0.02
IgM (g/l) 27 0.46 0.02 33 0.18 n.s.
CRP (mg/l) 26 0.09 n.s. 31 0.22 n.s.
Hb (mmol/l) 29 −0.45 0.02 35 −0.61 n.s.
Thrombocytes (*10E9/l)* 28 0.20 n.s. 34 0.03 n.s.
Lymphocytes (*10E9/l)* 26 0.03 n.s. 32 −0.11 n.s.
Neutrophils (*10E9/l) 26 −0.40 0.05 32 −0.18 n.s.
Variable N (%) Z p Value N (%) Z p Value
Autoantibodies
Anti-SSA 24/29 (83) −3.07 <0.01 30/35 (86) −2.40 0.02
Anti-Ro52 16/22 (73) −2.26 0.02 21/27 (78) −1.98 0.05
Anti-Ro60 15/22 (68) −3.02 <0.01 19/27 (70) −2.76 0.01
Anti-SSB 19/29 (66) −3.20 <0.01 23/35 (66) −1.63 n.s.
Medical therapy
Pilocarpine 7/29 (24) −1.36 n.s. 9/35 (26) −1.47 n.s.
Plaquenil 23/29 (79) −2.05 0.04 26/35 (74) −3.25 <0.01
Corticosteroids 2/29 (7) −1.64 n.s. 3/35 (9) −0.59 n.s.
Data are presented as Spearman’s rho (r) or according to κ2 test (Z), unless otherwise mentioned.
*Data normally distributed are presented as Pearson’s rho (r).
CRP, C-reactive protein; Hb, haemoglobin; n.s., not significant; Rf, rheumatoid factor.
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observed a strong correlation between the IFN type I signature
and BAFF mRNA in pSS monocytes.13 Moreover, we found
BAFF serum protein level increased in pSS compared with HC,
but did not find a correlation with the IFNscore; additionally,
BAFF serum protein did not correlate with BAFF mRNA. We
report here that BAFF protein levels showed a slight but not sig-
nificant increase in IFNpos patients, whereas BAFF mRNA was
indeed significantly increased in IFNpos patients. This again
indicates the lack of correlation between BAFF mRNA and
BAFF protein.
Some limitations of our study are for one, the relatively small
sample size for CD64. Assessing this surface marker in a large
set of patients is warranted to better understand its role in sys-
temic autoimmunity. Second, MxA-EIA levels were not assessed
for all subjects due to whole-blood necessity. Furthermore,
absence of viral infections was defined as ‘no symptoms of
underlying viral infections’ at inclusion, whereas no viral screen-
ing was done to confirm. In HC with relatively high MxA
levels, however, ENA profiles were run to rule out the presence
of autoantibody. Third, the ESSDAI as well as some clinical and
laboratory parameters were not assessed in all pSS patients.
In this study, we reconfirmed a monocyte IFN type I signa-
ture prevalence in over half of the pSS patients, a subgroup
with higher disease activity.13 We proposed the identification of
these subgroups useful in establishing a patient’s eligibility for
specific treatments. Indeed, an interesting finding here was that
patients on HCQ treatment had considerably reduced MxA
levels, indicating HCQ to perhaps interfere with IFN produc-
tion. A recent report shows HCQ to impair systemic IFNα pro-
duction.39 Our data suggest that identifying the IFN type I
signature by performing MxA assays might prove useful in pre-
dicting HQC treatment responsiveness. In this cohort, there
are more HCQ users in the IFNneg group compared with
IFNpos. However, it is not likely that the increased ESSDAI
levels in the IFNpos group are an effect of less HCQ use in
this group, because in the IFNpos group, 62% of the patients
use HCQ and are nevertheless IFNpos. Moreover, we previ-
ously showed 61% (23/38) of the IFNpos patients to use HCQ
compared with 55% (17/31) of IFNneg patients. In addition,
HCQ use did not significantly affect ESSDAI scores (figure
4H). Larger studies are, however, warranted to fully elucidate
the effects of HCQ on the IFN type I system, in particular,
longitudinal studies monitoring MxA levels in HCQ-naïve
patients starting HCQ treatment.
The association between the IFN type I signature, MxA protein
and disease activity levels in pSS needs to be further assessed, by
for one looking longitudinally, in order to validate MxA as a
disease activity marker. The same holds true for association
between IFN type I polymorphisms and MxA, as these poly-
morphisms have been linked to increased IFNα sensitivity.40 41
To determine the applicability of the MxA-EIA in other IFN
type I-related diseases, MxA levels were assessed in a small SLE
cohort (see online supplemental figure S4) and showed results
similar to pSS—a significant correlation between IFNscores and
MxA levels (r=0.885, p<0.0001)—suggesting a broad applic-
ability of MxA-EIA in systemic autoimmunity.
In conclusion, we identify MxA protein expression by EIA
and FACS analysis as practical and rapid approaches for assess-
ment of IFN type I bioactivity in pSS. MxA-EIA is the simplest
and most reliable of these assays and indicates clinical applicabil-
ity in stratifying pSS patients according to IFN positivity. The
use of MxA as a biomarker for identifying patients eligible for
therapy in pSS clearly requires further research.
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